



# Model List of Essential Medicines

## Anti-D immunoglobulin

Section	Indications
Human immunoglobulins	Rh incompatibility reaction
Parenteral > General injections > IV: 250 µg in single-dose vial	
Parenteral > General injections > IM: 250 µg in single-dose vial	Maternal care for red cell antibodies

## Anti-rabies immunoglobulin

Section	Indications
Human immunoglobulins	Rabies
Parenteral > General injections > IM: 150 IU per mL in vial	
Parenteral > Locoregional injections > Other: 150 IU per mL in vial	

## Anti-tetanus immunoglobulin

Section	Indications
Human immunoglobulins	Tetanus
Parenteral > General injections > IM: 500 IU in vial	

## C1 esterase inhibitor

Section	Indications
Plasma-derived medicines	Hereditary angioedema
Parenteral > General injections > IV: 500 IU in vial powder for injection	

## Coagulation factor IX

Section	Indications
Coagulation factors	Coagulation defects, purpura or other haemorrhagic or related conditions
Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection	Haemophilia B

## Coagulation factor IX complex

Section	Indications
Coagulation factors	Therapeutic equivalent to coagulation factor IX for Coagulation defects, purpura or other haemorrhagic or related conditions
	Therapeutic equivalent to coagulation factor IX for Haemophilia B

## Coagulation factor VIII

Section	Indications
Coagulation factors Parenteral > General injections > IV: 250 IU in vial powder for injection; 500 IU in vial powder for injection; 1000 IU in vial powder for injection	Haemophilia A

## Cryoprecipitate (not pathogen-reduced)

Section	Indications
Blood and blood components	Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for  Haemophilia A  Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for  Coagulation defects, purpura or other haemorrhagic or related conditions  Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for  Von Willebrand disease  Therapeutic equivalent to cryoprecipitate (pathogen-reduced) for  Obstetric haemorrhage

## Cryoprecipitate (pathogen-reduced)

Section	Indications
Blood and blood components  Injection: frozen liquid in bag or lyophilized powder in vial containing:  > 50 IU Factor VIII  > 100 IU vWF  > 140 mg clottable fibrinogen per unit	Haemophilia A  Coagulation defects, purpura or other haemorrhagic or related conditions  Von Willebrand disease  Obstetric haemorrhage

## Dextran 40

Section	Indications
Plasma substitutes	Hypovolaemia

## Dextran 70

Section	Indications
Plasma substitutes  Parenteral > General injections > IV: 6% injectable solution	Hypovolaemia

## Fresh-frozen plasma

Section	Indications
Blood and blood components Parenteral > General injections > IV:	Blood transfusion without reported diagnosis

## Normal immunoglobulin

Section	Indications
Human immunoglobulins Parenteral > General injections > IV: 5% protein solution; 10% protein solution Parenteral > General injections > IM: 16% protein solution Parenteral > General injections > SC: 15% protein solution; 16% protein solution	Primary immunodeficiencies Langerhans cell histiocytosis Mucocutaneous lymph node syndrome

## Platelets

Section	Indications
Blood and blood components Parenteral > General injections > IV:	Blood transfusion without reported diagnosis

## Polygeline

Section	Indications
Plasma substitutes Parenteral > General injections > IV: 3.5% injectable solution Parenteral > General injections > IV: 3.5% in solution	Therapeutic equivalent to dextran 70 for Hypovolaemia Hypovolaemia

## Red blood cells

Section	Indications
Blood and blood components Parenteral > General injections > IV:	Blood transfusion without reported diagnosis

## Whole blood

Section	Indications
Blood and blood components Parenteral > General injections > IV:	Blood transfusion without reported diagnosis